AbbVie wins hep C contract with Washington state in latest 'Netflix' deal

biopharmadive | April 26, 2019

AbbVie wins hep C contract with Washington state in latest 'Netflix' deal
Subscription-based contracts for pharmaceuticals is a relatively new concept. But it's one quickly moving into practice, with Louisiana and Washington both expecting to start these programs this summer.

One industry analyst predicts these programs could spread.

"We fully expect other states to step in and take advantage of these contracts," Ronny Gal, an analyst at Bernstein wrote in an email to BioPharma Dive. "The public health value is compelling."

Gal added that these types of deals also make sense for the companies, as long as the final discounts they concede are relatively modest. "The predictability of earnings is worth a lot," he added.

That's particularly the case in the hepatitis C market, where declining patient starts have made revenue growth a more uncertain prospect.

Washington hopes to finalize the contract and begin the program by July 1, Judy Zerzan, chief medical officer for the Washington State Health Care Authority, said in an interview with BioPharma Dive. That will coincide with the state completing the drafting of its broader plan to eliminate hep C in a decade.

Spotlight

Stem cells are primal cells found in all multi-cellular organisms. In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing specialized cells.

Spotlight

Stem cells are primal cells found in all multi-cellular organisms. In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing specialized cells.

Related News

Sutro Biopharma Demonstrates STRO-002's Immune-Modulating Properties at AACR 2020

Sutro Biopharma | June 22, 2020

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the presentation of new preclinical data for its folate receptor alpha (FolRα) targeting antibody-drug conjugate, STRO-002, at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020. The data, being presented by Sutro's Chief Scientific Officer, Trevor Hallam, Ph.D., demonstrates STRO-002's immune-modulating properties and potentiation by PD-L1 blockade.The results of the study showed that in FolRα positive tumor cells, STRO-002 treatment induced hallmarks of immunogenic cell death, killing tumor cells while activating immune cells, including monocytes. When combined in mouse tumor models with avelumab, an anti-human & mouse PD-L1 monoclonal antibody, the combination treatment enhanced efficacy leading to more complete responses and increased killer T cells, than either agent alone. Importantly, the data suggest that a single dose of STRO-002 when combined with a PD-1/PD-L1 blockade could provide an effective and protective anti-tumor immune response.

Read More

Repurpose.AI, LEO Pharma A/S Join Forces to Discover and Validate Drugs to Treat Inflammatory and Dermatology Indications

Repurpose.AI | July 01, 2020

Repurpose.AI, an AI drug discovery company, today announced the launch of an Open Innovation Partnership with LEO Pharma A/S, a global leader in medical dermatology, to discover and validate drugs to treat inflammatory and dermatology indications.The research collaboration will leverage Repurpose.AI's ActivPred AI Drug Discovery Platform, an unbiased drug, target and disease agnostic digital chemistry engine, to discover drug candidates for inflammatory skin diseases. Previously, the company has successfully utilized the platform to discover REP-001, REP-002 and REP-003 – three Phase II/III ready small molecule assets for the treatment of Gastric, Neurological and Weight disorders, respectively. LEO Pharma A/S will share inflammatory and dermatology targets they consider to be of interest and will evaluate compounds discovered by Repurpose.AI in disease assays for potential therapeutic use in inflammatory skin diseases.LEO Pharma is a 111-year-old, foundation-owned global pharmaceutical company with over 6,000 employees and 2019 revenues in excess of EUR 1.4B. LEO Pharma has a well-established product portfolio focusing on dermatology and skin inflammation diseases that provides help to 92 million people globally. LEO Pharma is constantly innovating, exploring new opportunities and ways of working with external research partners. To achieve this, LEO Pharma has established the Open Innovation platform, a collaborative space where unique research tools are made available to external partners to enable the discovery and validation of sector changing therapeutics for patients suffering from inflammatory and dermatology indications.

Read More

INDUSTRIAL IMPACT

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio

MeMed | January 10, 2022

MeMed, a leader in host response technologies, announces a $93 million private financing round, bringing total funding in the Company to over $200 million, including support from the U.S. Department of Defense and EU Commission. Funds will be used to scale up manufacturing, accelerate commercialization and expand MeMed’s pioneering host immune response product portfolio. MeMed’s technology suite decodes the body’s immune response within minutes, providing physicians with important patient management solutions that tackle key clinical dilemmas. The U.S. Food and Drug Administration (FDA) recently granted a landmark clearance for the use of the MeMed BV® test on the point-of-need platform MeMed Key®, to help healthcare providers distinguish between bacterial and viral infections in both children and adults. MeMed has also developed the MeMed COVID-19 Severity™ test for predicting severe outcomes in COVID-19 patients, which has been cleared for use in Europe. The latest financing brings together new and existing investors including Horizons Ventures, Shavit Capital, Social Capital, La Maison Partners, Touchwood Capital, Caesara Medical Holdings, Union Tech Ventures, ClaI Insurance, Phoenix Insurance, Poalim Equity and Western Technology Investment. “This new investment will enable MeMed to expand operations with a focus on the U.S. We are grateful to our investors for their support and will leverage the funds, the recent FDA clearance, and our growing network of partnerships to provide broad patient access to our technology, as well as expand our product portfolio of pioneering host response solutions.” Eran Eden, MeMed’s co-founder and CEO Patrick Zhang, Horizons Ventures, said: “We strongly believe that MeMed’s strategy of using host immune response technologies is a significant advance in the improvement of two major issues in healthcare today: the rise of antimicrobial resistance due to unnecessary prescription of antibiotics and effectively triaging patients infected with COVID-19. We look forward to playing a role in how MeMed, a category leader in this area, is transforming the way diseases are diagnosed and treated to improve patient healthcare across the globe.” About MeMed Our mission is to translate the immune system's complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society.

Read More